查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1949579

ATP 檢測市場 - 全球產業規模、佔有率、趨勢、機會及預測（按類型、應用、最終用途、地區和競爭格局分類，2021-2031 年）

ATP Assays Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 ATP 檢測市場預計將從 2025 年的 36.3 億美元成長到 2031 年的 56.9 億美元，複合年成長率為 7.78%。

此細分市場主要包括利用生物發光技術測量三Adenosine(ATP) 的生化診斷解決方案，ATP 可快速指示細胞活力和微生物污染情況。推動該細分市場成長的主要因素是製藥業日益嚴格的監管要求，例如歐盟 GMP 附錄 1，以及食品飲料產業為避免安全事故而對即時衛生檢驗日益成長的需求。這些關鍵促進因素獨立於攜帶式偵測裝置與雲端資料分析結合的新興技術變革而發揮作用。

市場概覽
預測期 2027-2031
市場規模：2025年 36.3億美元
市場規模：2031年 56.9億美元
複合年成長率：2026-2031年 7.78%
成長最快的細分市場 發光法ATP測定
最大的市場 北美洲

這些衛生通訊協定在高風險環境中的有效性已得到證實，這進一步凸顯了此類快速監測設備的必要性。 2024年美國醫院協會（AHA）的數據顯示，醫院中央靜脈導管相關血流感染率年減15%，凸顯了這些檢測方法所支持的嚴格表面監測的關鍵作用。儘管取得了這些進展，但市場仍面臨一個顯著的障礙：標準ATP檢測固有的特異性不足。標準ATP檢測無法區分微生物殘留和有機殘留，這使得污染源的識別變得複雜，並限制了其更廣泛的應用。

市場促進因素

生物技術和製藥行業研發投入的不斷成長正推動資源流向毒性測試和臨床前研究，成為全球ATP檢測市場的主要驅動力。隨著企業投入大量資金開發新型療法，對可靠的細胞毒性和細胞活力檢測的需求也相應成長，而ATP檢測因其快速和靈敏的優勢而備受青睞。這些投資使得企業能夠購買用於藥物候選物早期嚴格評估的先進生物發光試劑和試劑盒。根據美國藥品研究與製造商協會（PhRMA）於2024年9月發布的《2024年PhRMA會員調查報告》，會員企業2023年的研發投入將達到創紀錄的1035億美元，這與實驗室對代謝監測工具的日益普及直接相關。

同時，癌症和慢性疾病發生率的不斷上升正在加速依賴高通量篩檢技術的藥物研發。尤其是在腫瘤學領域，代謝活性被用於評估癌細胞的健康狀況，實驗室越來越依賴基於ATP的生物發光技術來評估龐大的化合物庫對特定疾病模型的療效。美國癌症協會於2024年1月發布的《2024年癌症事實與數據》報告預測，當年美國將新增2,001,140例癌症病例，凸顯了推動此類篩檢的巨大臨床需求。這些努力的成功也體現在監管方面的成果中，美國食品藥物管理局（FDA）在2024年宣布，前一年已核准了55種新的治療藥物。這顯示，藥物研發管線十分強大，需要在整個研發過程中持續應用代謝譜分析工具。

市場挑戰

全球ATP檢測市場面臨的主要障礙是標準生物發光檢測固有的非特異性。這些檢測無法區分有害微生物污染和無害有機殘留物。這項技術缺陷顯著限制了ATP檢測在關鍵控制領域的應用，而準確識別污染源至關重要。如果檢測結果呈陽性，操作人員無法確定ATP水平升高是表示存在有害病原體，還是僅僅表示食品安全。這種不確定性迫使生產者依賴其他更耗時的檢測方法，例如聚合酵素鏈鎖反應（PCR），來確認殘留物的性質，從而阻礙了ATP檢測作為一種全面、獨立的診斷工具發揮作用。

這種特異性的缺失嚴重阻礙了其在敏感領域（例如無過敏原食品生產和製藥無塵室）的市場推廣。隨著消費者對細菌安全性的日益重視，無法提供病原體特異性檢驗的問題尤其突出。根據國際食品資訊理事會 (IFIC) 2024 年的一項調查，僅有 62% 的消費者對美國食品供應的安全性表示有信心，47% 的消費者將細菌性食源性疾病列為他們最關心的問題。這凸顯了市場上的一個缺口：ATP 檢測的通用檢測能力無法滿足細菌檢驗的特定要求，從而有效地抑制了需要絕對病原體確認的領域的發展。

市場趨勢

將ATP檢測方法應用於類器官模型和3D細胞培養，代表臨床前藥物研發領域的重大技術革新，突破了傳統單層培養測試的限制。隨著製藥公司優先考慮生理學上精確的模型以降低後期臨床試驗的失敗率，對能夠有效裂解高密度球狀體並精確量化其活性的專用ATP試劑的需求激增。大型合約研發生產機構（CDMO）不斷擴展其高內涵篩檢能力，也印證了這項轉變。例如，三星生物製劑公司在2025年12月宣布，已於2025年6月推出專門的類器官服務，旨在提高國際客戶臨床研究的柔軟性和速度，從而策略性地擴展其產品組合。

同時，在醫療設備再處理通訊協定中應用快速ATP檢測正在改變醫療機構的衛生合規性。為了應對日益成長的環境和成本壓力，醫院正在迅速擴大對再處理一次性醫療設備的使用。這種做法需要在滅菌前進行嚴格的清潔檢驗，以防止感染傳播。這種擴張直接推動了ATP生物發光檢測作為關鍵品管標準的應用。根據醫療設備再處理協會（AMDR）2025年4月的一項研究，到2024年，美國醫院透過使用受監管的再處理設備，可節省超過4.51億美元的成本。這凸顯了需要進行標準化清潔度檢驗的大量庫存。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球ATP檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（發光 ATP 檢測、酶 ATP 檢測、生物發光共振能量轉移 (BRET) ATP 檢測、基於細胞的 ATP 檢測、其他）
    • 按應用領域（藥物發現與開發、臨床診斷、環境檢測、食品安全與品質檢測等）
    • 按最終用途（製藥和生物技術公司、學術和研究機構、醫院和診斷檢查室）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美ATP檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲ATP檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區ATP檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲ATP檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美ATP檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球ATP偵測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Thermo Fisher Scientific Inc.
  • Promega Corporation
  • PerkinElmer Inc.
  • Becton, Dickinson and Company（BD）
  • Lonza Group AG
  • DH Life Sciences, LLC.
  • Abcam Limited
  • Quest Diagnostics Incorporated
  • BIOMeRIEUX SA
  • 3M Company

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 25424

The Global ATP Assays Market is projected to expand from a valuation of USD 3.63 Billion in 2025 to USD 5.69 Billion by 2031, registering a CAGR of 7.78%. This sector comprises biochemical diagnostic solutions that measure Adenosine Triphosphate, largely through bioluminescence, to serve as rapid indicators of cellular viability and microbial contamination. Growth is principally driven by strict regulatory requirements in pharmaceutical production, such as EU GMP Annex 1, alongside an increasing necessity for real-time hygiene verification in the food and beverage sector to avert safety incidents. These core drivers operate independently of the emerging technological shift toward combining handheld testing units with cloud-based data analytics.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.63 Billion
Market Size 2031USD 5.69 Billion
CAGR 2026-20317.78%
Fastest Growing SegmentLuminometric ATP Assays
Largest MarketNorth America

The proven effectiveness of these sanitation protocols in high-stakes environments reinforces the need for such rapid monitoring instruments. Data from the American Hospital Association in 2024 indicates that hospitals realized a 15% decrease in central line-associated bloodstream infections compared to the prior year, highlighting the critical role of the rigorous surface monitoring enabled by these assays. Despite this progress, the market encounters a notable obstacle regarding the inherent lack of specificity in standard ATP tests, which fail to distinguish between microbial and organic residues, thereby complicating the identification of contamination sources and limiting wider adoption.

Market Driver

Increasing expenditure on research and development within the biotechnology and pharmaceutical sectors acts as a primary catalyst for the Global ATP Assays Market by boosting resources for toxicity testing and preclinical studies. As corporations commit substantial capital to creating new therapeutics, the requirement for dependable cytotoxicity and cell viability assays rises accordingly, with ATP detection preferred for its speed and sensitivity. This financial investment enables the acquisition of sophisticated bioluminescent reagents and kits necessary for the strict early-phase assessment of drug candidates. According to the '2024 PhRMA Annual Membership Survey' released by the Pharmaceutical Research and Manufacturers of America in September 2024, member companies directed $103.5 billion toward research and development in 2023, a record amount that correlates directly with higher laboratory usage of metabolic monitoring tools.

Concurrently, the growing incidence of cancer and chronic diseases is quickening drug discovery efforts that depend on high-throughput screening techniques. Laboratories rely increasingly on ATP-based bioluminescence to evaluate extensive compound libraries for effectiveness against specific disease models, especially in oncology where tumor cell health is gauged by metabolic activity. The American Cancer Society's 'Cancer Facts & Figures 2024' report from January 2024 projects 2,001,140 new cancer cases in the United States for the year, highlighting the critical clinical demand driving this screening. The success of these initiatives is reflected in regulatory achievements; the U.S. Food and Drug Administration noted in 2024 that 55 novel therapeutics were approved the previous year, indicating a strong pipeline that requires the persistent application of metabolic profiling tools throughout development.

Market Challenge

The central obstacle hindering the Global ATP Assays Market is the intrinsic non-specificity associated with standard bioluminescence testing, which fails to distinguish between hazardous microbial contamination and benign organic residues. This technical shortcoming significantly limits the application of ATP assays in critical control settings where accurate identification of contamination sources is mandatory. When a test result is positive, operators are unable to determine if the elevated ATP readings signify the presence of harmful pathogens or merely safe food byproducts. This uncertainty frequently compels manufacturers to rely on additional, slower testing methods like Polymerase Chain Reaction (PCR) to verify the residue's nature, preventing ATP assays from serving as a comprehensive standalone diagnostic tool.

As a result, this lack of specificity presents a major hurdle to market adoption in sensitive sectors such as allergen-free food manufacturing and pharmaceutical cleanrooms. The inability to offer pathogen-specific validation is especially damaging given the growing consumer emphasis on bacterial safety. According to the International Food Information Council in 2024, only 62% of consumers reported confidence in the safety of the U.S. food supply, with 47% identifying foodborne illness caused by bacteria as their primary worry. This evidence highlights a gap in the market where the general detection capacity of ATP assays falls short of the specific requirement for bacterial verification, effectively impeding growth in segments that demand absolute confirmation of pathogens.

Market Trends

Incorporating ATP assays into organoid models and 3D cell cultures marks a significant technical evolution in preclinical drug development, advancing beyond the constraints of conventional monolayer testing. As pharmaceutical firms prioritize physiologically accurate models to decrease late-stage clinical attrition, there is a surging demand for specialized ATP reagents designed to effectively lyse dense spheroids for precise viability quantification. This shift is further illustrated by leading contract development and manufacturing organizations broadening their capacities for high-content screening. For instance, Samsung Biologics reported in December 2025 that it strategically expanded its portfolio by introducing a dedicated organoid service in June 2025, aimed at improving clinical research flexibility and speed for its international clients.

Simultaneously, the application of rapid ATP testing within medical device reprocessing protocols is transforming hygiene compliance in healthcare settings. Faced with increasing pressure to reduce environmental impact and costs, hospitals are rapidly scaling their use of reprocessed single-use devices, a practice that demands strict cleaning verification prior to sterilization to avert infection transmission. This operational expansion directly fuels the use of ATP bioluminescence tests as a primary quality control standard. According to an April 2025 survey by the Association of Medical Device Reprocessors, U.S. hospitals realized over $451 million in savings in 2024 by utilizing regulated reprocessed devices, highlighting the massive inventory volume that now necessitates standardized validation of cleanliness.

Key Market Players

  • Thermo Fisher Scientific Inc.
  • Promega Corporation
  • PerkinElmer Inc.
  • Becton, Dickinson and Company (BD)
  • Lonza Group AG
  • DH Life Sciences, LLC.
  • Abcam Limited
  • Quest Diagnostics Incorporated
  • BIOMeRIEUX S.A.
  • 3M Company

Report Scope

In this report, the Global ATP Assays Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

ATP Assays Market, By Type

  • Luminometric ATP Assays
  • Enzymatic ATP Assays
  • Bioluminescence Resonance Energy Transfer (BRET) ATP Assays
  • Cell-based ATP Assays
  • Others

ATP Assays Market, By Application

  • Drug Discovery and Development
  • Clinical Diagnostics
  • Environmental Testing
  • Food Safety and Quality Testing
  • Others

ATP Assays Market, By End Use

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Hospital and Diagnostics Laboratories

ATP Assays Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global ATP Assays Market.

Available Customizations:

Global ATP Assays Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global ATP Assays Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Luminometric ATP Assays, Enzymatic ATP Assays, Bioluminescence Resonance Energy Transfer (BRET) ATP Assays, Cell-based ATP Assays, Others)
    • 5.2.2. By Application (Drug Discovery and Development, Clinical Diagnostics, Environmental Testing, Food Safety and Quality Testing, Others)
    • 5.2.3. By End Use (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Hospital and Diagnostics Laboratories)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America ATP Assays Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End Use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States ATP Assays Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End Use
    • 6.3.2. Canada ATP Assays Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End Use
    • 6.3.3. Mexico ATP Assays Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End Use

7. Europe ATP Assays Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End Use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany ATP Assays Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End Use
    • 7.3.2. France ATP Assays Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End Use
    • 7.3.3. United Kingdom ATP Assays Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End Use
    • 7.3.4. Italy ATP Assays Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End Use
    • 7.3.5. Spain ATP Assays Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End Use

8. Asia Pacific ATP Assays Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End Use
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China ATP Assays Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End Use
    • 8.3.2. India ATP Assays Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End Use
    • 8.3.3. Japan ATP Assays Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End Use
    • 8.3.4. South Korea ATP Assays Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End Use
    • 8.3.5. Australia ATP Assays Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End Use

9. Middle East & Africa ATP Assays Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End Use
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia ATP Assays Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End Use
    • 9.3.2. UAE ATP Assays Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End Use
    • 9.3.3. South Africa ATP Assays Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End Use

10. South America ATP Assays Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End Use
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil ATP Assays Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End Use
    • 10.3.2. Colombia ATP Assays Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End Use
    • 10.3.3. Argentina ATP Assays Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global ATP Assays Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Promega Corporation
  • 15.3. PerkinElmer Inc.
  • 15.4. Becton, Dickinson and Company (BD)
  • 15.5. Lonza Group AG
  • 15.6. DH Life Sciences, LLC.
  • 15.7. Abcam Limited
  • 15.8. Quest Diagnostics Incorporated
  • 15.9. BIOMeRIEUX S.A.
  • 15.10. 3M Company

16. Strategic Recommendations

17. About Us & Disclaimer